The Ministry of Health, Labor and Welfare (MHLW) on November 29 proposed a more stringent application of the current 40% entry price rule for first oral generics towards the FY2024 drug pricing reform.Under the current rule, first oral generics are…
BUSINESS
Pivotal Focus for Biosimilars Business on Japan: Daiichi Sankyo President Nakayama
Joji Nakayama, president and CEO, Daiichi Sankyo, said at a management briefing held on May 14 concerning the biosimilars business, for which the company has indicated its intent for market entry with an alliance with a US company, that “In…
To read the full story
BUSINESS
- Abecma Approved for Earlier Lines of MM Therapy in Japan: BMS
December 7, 2023
- Pfizer to Cut Ties with 3 Regional Wholesalers, Further Narrowing Expected
December 5, 2023
- Shionogi Hooks Up with Life Science VC AN Venture Partners
December 5, 2023
- Preliminary Injunction for Sprycel Generic “Extremely Unjust”: Sawai
December 5, 2023
- Ono Doubles Investment in Corporate Venture Fund to US$200 Million
December 4, 2023
Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
A member of the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry on November 13…
A health ministry study group on pharmaceutical regulations on October 13 roughly agreed on a reform plan for Japanese regulatory…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…